Trial Profile
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Irinotecan; Temozolomide
- Indications CNS cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 13 Oct 2023 Protocol has been amended to change in time frame for Toxicities Associated With Pevonedistat in Combination With Irinotecan and Temozolomide Up to 3 years 8 months
- 13 Oct 2023 Planned End Date changed from 5 Oct 2022 to 22 Sep 2024.
- 23 Mar 2022 Planned End Date changed from 31 Dec 2021 to 5 Oct 2022.